INTERNATIONAL JOURNAL OF NOVEL RESEARCH AND DEVELOPMENT International Peer Reviewed & Refereed Journals, Open Access Journal ISSN Approved Journal No: 2456-4184 | Impact factor: 8.76 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.76 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
Dapagliflozin ( Forxiga®) is a globally recognized treatment for type 2 diabetes, known for its high potency, reversibility, and selectivity as a sodium-glucose cotransporter-2 inhibitor. Dapagliflozin, taken orally once daily, is approved in the EU for use as monotherapy (in patients intolerant of metformin) and as an add-on combination therapy (with other glucose-lowering agents, including insulin) for T2D when diet and exercise alone are insufficient for adequate glycemic control. Dapagliflozin, whether used alone or in combination with other
Antihyperglycemic agents, demonstrated effective glycemic control and led to reductions in body weight and blood pressure in a wide range of patients, as evidenced by numerous meticulously conducted clinical studies and their extensions. Dapagliflozin decreased the occurrence of cardiovascular (CV) death or hospitalization for heart failure (HHF), showed no negative impact on major adverse CV events (MACE), and potentially slowed the progression of renal disease compared to a placebo in individuals with confirmed atherosclerotic CV disease (CVD) or multiple CVD risk factors. Dapagliflozin was generally well received, exhibiting a minimal risk of hypoglycemia. While diabetic ketoacidosis (DKA), though infrequent, genital infections were more prevalent with dapagliflozin compared to the placebo. Due to its antihyperglycemic, cardioprotective, and potentially reno protective attributes, along with a generally well-tolerated profile, dapagliflozin emerges as a significant choice for treating a Adiverse range of patients, irrespective of their cardiovascular history.
Keywords:
Dapagliflozin, Type 2 diabetes, cardiovascular disease, Adverse event.
Cite Article:
"DAPAGLIFLOZIN: FOR THE TREATMENT OF TYPE - 2 DIABETES", International Journal of Novel Research and Development (www.ijnrd.org), ISSN:2456-4184, Vol.9, Issue 1, page no.d130-d139, January-2024, Available :http://www.ijnrd.org/papers/IJNRD2401317.pdf
Downloads:
000118757
ISSN:
2456-4184 | IMPACT FACTOR: 8.76 Calculated By Google Scholar| ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.76 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Facebook Twitter Instagram LinkedIn